Promising results using next-generation DCs loaded with WT1, PRAME, and CMVpp65 and cultured with TLR agonists were obtained in 10 AML patients in first CR with the non-favorable risk group or MRD positivity [27]. This evidence concerns the gene WT1 and acute myeloid leukemia.